Erasca names Charles Fuchs as President of Research & Development

Erasca, Inc. announced in an 8-K that Charles S. Fuchs, M.D., M.P.H., was appointed President, Research & Development of the company, effective August 10, 2026.¹

Dr. Fuchs, 66, is described by the company as a physician-scientist with an extensive background spanning cancer research, clinical care, and drug development over more than 30 years.¹ Most recently, he served as Chief Medical Officer of Tubulis GmbH, a company later acquired by Gilead, from December 2025 to August 2026, where he was responsible for clinical strategy and pipeline development.¹ Before that role, he spent roughly four years, from March 2021 to December 2025, leading oncology and hematology product development globally for Genentech and its parent Roche.¹

Earlier in his career, Dr. Fuchs directed the Yale Cancer Center and served as Physician-in-Chief at Smilow Cancer Hospital between January 2017 and February 2021.¹ Before that, he held an academic post as a medicine professor at Harvard Medical School and led the gastrointestinal oncology division at Dana-Farber Cancer Institute, holding the Robert T. and Judith B. Hale Chair in Pancreatic Cancer, from July 2007 to December 2016.¹ He currently also sits on the board of CytomX Therapeutics and advises Frazier Life Sciences.¹

His compensation package, per the filing, includes an annual base salary of $570,000, a target bonus equal to 45% of base salary, and a stock option grant for 1,300,000 shares of common stock.¹ The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment.¹ Of these options, 1,278,520 were granted under the company's new 2026 Employment Inducement Incentive Award Plan, with the rest issued under the 2021 Incentive Award Plan.¹

Separately, the board also adopted the Inducement Plan effective the same day, reserving 6,200,000 shares for equity awards under it.¹